Yang Zijiang Pharmaceutical Group was established in 197 1, which is a large pharmaceutical enterprise group in China, combining science, technology, industry and trade. Headquartered in Taizhou City, Jiangsu Province, a famous city in the Yangtze River Delta, it has more than 5,000 employees with total assets of 5 billion yuan and a total area of about 2 million square meters. The core of the group is Changjiang Pharmaceutical Group Co., Ltd., with more than 65,438+00 member enterprises. Including Changjiang Pharmaceutical Group Jiangsu Pharmaceutical Co., Ltd., Changjiang Pharmaceutical Group Beijing Haiyan Pharmaceutical Co., Ltd., Changjiang Pharmaceutical Group Shanghai Heini Pharmaceutical Co., Ltd., Changjiang Pharmaceutical Group Nanjing Hailing Pharmaceutical Co., Ltd., Changjiang Pharmaceutical Group Sichuan Hairong Pharmaceutical Co., Ltd., Changjiang Pharmaceutical Group Guangzhou Hairui Pharmaceutical Co., Ltd., Changjiang Pharmaceutical Group Jiangsu Haici Biopharmaceutical Co., Ltd. ... All the production plants and dosage forms of the group have passed the national GMP certification, and have an annual extraction capacity of 1 10,000 tons of Chinese medicine extraction production base.
Since its establishment, Yang Zijiang Pharmaceutical Co., Ltd. has been aiming at making the pharmaceutical industry bigger and stronger and becoming an international enterprise, constantly accelerating the pace of scientific and technological innovation and independent brand building, building the core competitiveness of the enterprise, and the comprehensive economic strength of the enterprise has been rapidly improved. Since 1996, the comprehensive economic benefits have ranked first among pharmaceutical enterprises in Jiangsu for 9 consecutive years. Since 1997, it has been ranked in the top five of more than 6,300 pharmaceutical enterprises in China for eight consecutive years. In 2004, the group's sales revenue and profit and tax indicators both jumped to the top of the national pharmaceutical enterprises, becoming the new main champion of China pharmaceutical enterprises, and ranking among the top 500 largest enterprise groups in China and the top 500 taxpayers in China.
In the development of enterprises. Yang Zijiang Pharmaceutical Group adheres to the development road of "invigorating enterprises through science and technology" and "strengthening enterprises through science and technology", and has formulated a new product development strategy of "three highs and one specialty", which is characterized by high scientific and technological content, high added value, large market capacity and unique curative effect. Every year, enterprises spend more than 1 100 million yuan on technological innovation and development. In addition to independent research, we also cooperate with famous academicians, experts and research institutions of major universities in China through the joint efforts of Industry-University-Research. Since 1996, more than 15 new drugs have been developed every year on average, of which about half are independently developed. In 2000, the Group Technology Center was approved by the Ministry of Science and Technology of the State Economic and Trade Commission as a "national technology center". In 2003, the National Development and Reform Commission and the Jiangsu Provincial Government invested and approved the establishment of Nanjing Hailing National Engineering Research Center for Chinese Medicine and Pharmaceutical Technology, dedicated to the modernization and internationalization of Chinese medicine. In addition, the Group has set up scientific research centers in subsidiaries such as Beijing, Shanghai, Nanjing and Chengdu, and transferred the tentacles of scientific research to big cities. At present, Yang Zijiang Pharmaceutical Group has built several R&D platforms. First, the national enterprise technology center of the group headquarters is the main body to build a technical platform for chemical drug research and development. The second is to build a modern Chinese medicine research and development technology platform with Nanjing Hailing National Engineering Research Center of Chinese Medicine Pharmaceutical Technology as the main body. The third is to build four new product research and development platforms of subsidiaries with new product departments in Shanghai and Beijing as the main body. Fourth, cooperate with high-level R&D personnel at home and abroad to build a joint laboratory. For example, the cooperative laboratory between the Group and Dr. Han Wei of Merck Company in the United States passed the certification of four large American pharmaceutical companies headed by Merck Company in the United States, and successfully synthesized more than 1000 brand-new compounds for efficacy screening. On the other hand, it is transforming 50- 100 brand-new compounds that have been initially proved to be effective in treating diabetes and AIDS; We have reached an agreement with Dr. Du from Stanford University in the United States to develop an innovative variety for myocardial cell protection, and the project has been started.
After more than 30 years of accumulation and innovation, Yang Zijiang Pharmaceutical Group has now formed a product group with more than 10 series, more than 10 dosage forms and more than 100 specifications, which is mainly based on traditional Chinese medicine and combines traditional Chinese and western medicine, covering antibiotics, digestive system drugs, circulatory system drugs, anti-tumor drugs and antipyretic and analgesic drugs. The company mainly produces tablets, capsules, granules, oral liquids, syrups, ointments, freeze-dried powder injections, large-capacity injections, small-capacity injections and other1products, of which 5 products have been approved by the National Development and Reform Commission for independent pricing, 7 products have been listed as "national protected varieties of traditional Chinese medicine" and 8 products have been rated as "China well-known trademarks", with a total of more than 90 varieties. Qin Lan Oral Liquid, Jingqianping Granule, Ou Su, Zuo Ke and other products were recognized as "good products with reliable quality certified by national authoritative organizations" by China Quality Certification Standards Association, Yiling Weitong Granule was listed as "basic medicine for emergency treatment in Chinese medicine hospitals", Jingqianping Granule was listed as "key promotion project" by Chinese Medical Association, and the fist product "Su Wei Granule" was awarded as "China product quality user" jointly investigated by authoritative newspapers, authoritative associations and authoritative websites.
Yang Zijiang Pharmaceutical Group pays attention to building a people-oriented corporate culture and strives to build a harmonious enterprise. While vigorously developing the economy, the Yangtze River has always adhered to the corporate philosophy of "seeking progress and protecting all beings" and given full support in industrial construction, health education, poverty alleviation and disaster relief, and army building. Really return to society. The Group exclusively supports the "China Medical Science and Technology Award", the highest science and technology award in China's medical and health industry, subsidizes the "Wu Jieping Medical Fund" and other discipline funds, and widely supports the academic activities of the Chinese Medical Association, the Chinese Medical Association, the China Hospital Management Association and the Chinese Medical Doctor Association. For three consecutive years since 200 1, with the strong support of the Ministry of Health, the the State Council Poverty Alleviation Office, the the State Council Committee on Aging, the All-China Women's Federation and the State Administration of Radio, Film and Television, the Group has invested more than 40 million yuan to launch the "Care for Western Health Action" to "send doctors, medicines and knowledge" to more than 0 provinces, cities and autonomous regions in the western region1. The group also invested hundreds of thousands of yuan to set up a medical team to provide free sight-seeing surgery for poor elderly cataract patients in the western region. In 2003, in the fight against SARS, Changjiang donated medicines worth 5 million yuan to national medical and health institutions, and established the "Yangtze River Anti-Africa Relief Fund", fulfilling the social responsibility of an excellent pharmaceutical company.
Facing the future, Yang Zijiang Pharmaceutical Group is vigorously implementing the internationalization strategy. At present, as the leading park of "One Valley and Six Parks", a major development project along the Yangtze River in Jiangsu Province, the Yangtze River Pharmaceutical Industrial Park covers an area of 570 mu, and will have an annual production capacity of 3 billion yuan after it is put into production. By 2008, the Group has built six production bases and six R&D centers, extending its production and scientific research tentacles to "Beijing-Tianjin-Tangshan", "Pearl River Delta" and "Yangtze River Delta", making Changjiang Medical City the largest pharmaceutical industry cluster in the economic belt along the Yangtze River in China. With the successful implementation of the Group's strategic layout in Thailand, Nanjing, Shanghai, Sichuan, Beijing and Guangzhou, the Yangtze River will take a more solid step in participating in international market competition. The advancing Changjiang Pharmaceutical Group, like the endless surging Yangtze River, wholeheartedly serves the health of all mankind with the feelings of serving the country through industry.
Suzhong pharmacy
Suzhong Pharmaceutical Co., Ltd. is a comprehensive production enterprise with a history of 30 years, specializing in the production and manufacture of drugs. Over the years, in terms of Chinese and western medicine preparations, we have continuously provided the market with more than 100 varieties of excellent pharmaceutical products. Because of its long history, the Soviet Union is more flexible in the development of high-tech bioengineering and genetically modified drugs, and has created one high-tech drug after another with exclusive patents, such as Huang Kui, Coriolus versicolor capsules and Shengmai. Not only at home, but also in the world.
Experts and scholars spoke highly of it. At present, Suzhong has developed into a large-scale comprehensive pharmaceutical factory with the concept of a framed pharmacological research base (medical city), and there are only a handful in China.
Suzhong Pharmaceutical China is headquartered in Jiangyan City, Jiangsu Province, China, with a factory area of over 300,000 square meters. Solid preparation and liquid preparation workshops are built in full accordance with the most authoritative international preparation factory standards, and after strict testing, they have obtained internationally recognized GMP certificates of high-quality production standards.
In the research and development of new drugs, Suzhong Pharmaceutical has invested heavily every year, and it is a great honor to set up a postdoctoral workstation. We have cooperated with advanced pharmaceutical factories in Europe and America, established a perfect drug research center, and engaged in a series of research and development on fermentation, synthesis and preparation. Because the traditional strain improvement technology is quite mature, Suzhong has begun to establish technology in genetic engineering and biotransformation, and the application of bioengineering transformation technology to develop API intermediates is expected to create innovative achievements and status in biotechnology in the future.
Suzhong Pharmaceutical has more than 65,438+0,000 employees in Greater China, of which more than a quarter are professional technicians. Because the advantages of enterprises in talent training and reserve are enough to make Suzhong proud in the pharmaceutical high-tech field. We have begun to expand the most advanced automatic drug production line in the world, and are actively standardizing and passing FDA certification, hoping to give back to customers with more advanced technology and more internationally competitive products.
Brief introduction of Jiangsu Jichuan pharmaceutical group
Jichuan Medicine, located in the beautiful Yangtze River Delta, has a good location advantage and a three-dimensional transportation network. Its core business covers chemical industry foundation, modern Chinese medicine preparation, Chinese medicine decoction pieces processing, pharmaceutical commercial wholesale, pharmaceutical raw materials, medical devices and other industries, and gradually forms a "Jichuan Pharmaceutical Industrial Park" covering an area of 1.500 mu.
Jichuan Medicine has a high-level pharmaceutical R&D system, a manufacturing and quality inspection system that has passed the national GMP certification, and a nationwide marketing network system, thus laying the foundation for the core competitiveness of the medical health industry.
Jichuan medicine has six series 150 quasi-brand drugs in more than 50 countries, including anti-infection, anesthesia, cerebrovascular disease, nutrition, sedation and detoxification, and digestive system. The main products, Luo Kang series and Zinuo, an anti-ulcer drug, were rated as "Jiangsu High-tech Products", and lidocaine carbonate injection was listed as "National Torch Plan Project", which is one of the professional pharmaceutical enterprises with the largest variety and dosage forms in pediatrics in China.
Jichuan Medicine has been ranked as one of the top 100 pharmaceutical industries in China for four consecutive years, and has always followed the enterprise spirit of "helping each other in the same boat, embracing the business philosophy of" science and technology protect health ",striving to enhance its brand image, creating a good corporate culture, and constantly making the enterprise stronger, bigger and longer.